Correction of Psoriatic T Cell Signatures by Deucravacitinib

Last updated: June 25, 2024
Sponsor: University of California, San Francisco
Overall Status: Active - Recruiting

Phase

4

Condition

Psoriasis And Psoriatic Disorders

Rosacea

Rash

Treatment

deucravacitinib

Clinical Study ID

NCT05858645
22-37660
  • Ages 18-75
  • All Genders

Study Summary

This study aims to assess cutaneous and blood immune cell function of patients with psoriasis before and after initiation of treatment with the Tyrosine kinase 2 (TYK2) blocker, deucravacitinib.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  1. 18 years of age or older

  2. Patients with moderate-severe psoriasis (BSA >= 10%, PASI >=12, static Physician'sGlobal Assessment (sPGA) 3 and above)

Exclusion

Exclusion Criteria:

  1. taking systemic immunosuppressives in the last 12 weeks

  2. pregnancy

  3. severe immunodeficiency (either from genetic or infectious causes).

  4. tuberculosis or other active serious infection

  5. active systemic malignancy.

  6. breast-feeding

  7. Presence of a condition or abnormality that in the opinion of the Investigator wouldcompromise the safety of the patient or the quality of the data.

Study Design

Total Participants: 25
Treatment Group(s): 1
Primary Treatment: deucravacitinib
Phase: 4
Study Start date:
October 01, 2023
Estimated Completion Date:
June 30, 2026

Study Description

This is a one-arm, open-label study to examine the effect of deucravacitinib on cutaneous and blood immune cells of psoriatic patients. 25 subjects with moderate to severe psoriasis will be enrolled. Biopsy and blood samples will be collected before and during treatment and undergo molecular profiling to assess for deucravacitinib-corrected signatures.

Connect with a study center

  • University of California, San Francisco

    San Francisco, California 94115
    United States

    Active - Recruiting

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.